We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current IMVT market cap is 3.42B. The company's latest EPS is USD -1.7668 and P/E is -13.20.
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -78.48M | -61.8M | -61.55M | -80.88M | -94.28M |
| Net Income | -73.94M | -58.66M | -51.42M | -75.32M | -87.15M |
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -66.08M | -108.12M | -156.03M | -218.28M | -282.71M |
| Net Income | -66.39M | -107.43M | -156.73M | -210.96M | -259.34M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 351.22M | 292.07M | 711.45M | 666.37M | 589.68M |
| Total Liabilities | 51.36M | 40.26M | 32.1M | 48.61M | 45.02M |
| Total Equity | 299.87M | 251.81M | 679.34M | 617.76M | 544.66M |
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 109.39M | 412.49M | 515.56M | 405.84M | 666.37M |
| Total Liabilities | 15.32M | 21.01M | 45.74M | 43.34M | 48.61M |
| Total Equity | 94.07M | 391.48M | 469.83M | 362.49M | 617.76M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -47.37M | -107.43M | -154.53M | -214.23M | -76.2M |
| Investing | -45k | -79k | -210k | -360k | -182k |
| Financing | 890k | 1.04M | 470.88M | 472.43M | 686k |
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -53.36M | -83.33M | -106.11M | -188.19M | -214.23M |
| Investing | -31k | -210k | -254k | -197k | -360k |
| Financing | 146.97M | 383.11M | 200.13M | 70.89M | 472.43M |
| Market Cap | 3.42B |
| Price to Earnings Ratio | -13.20 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 5.39 |
| Price to Book Ratio | 5.54 |
| Dividend Yield | - |
| Shares Outstanding | 146.78M |
| Average Volume (1 week) | 667.01k |
| Average Volume (1 Month) | 960.85k |
| 52 Week Change | -46.88% |
| 52 Week High | 44.45 |
| 52 Week Low | 23.075 |
| Spread (Intraday) | 0.04 (0.17%) |
| Company Name | Immunovant Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.immunovant.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
